A just-published report on the UK's life sciences sector "ought to ring alarm bells across government," according to the Association of the British Pharmaceutical Industry (ABPI).<
A pilot study has been launched by the EMA to see whether it is helpful for regulators to look at the 'raw data' from clinical trials submitted in support of new marketing application along
